FDA Approves New Combination Therapy for Muscle-Invasive Bladder Cancer

The FDA has approved a perioperative regimen of durvalumab and enfortumab vedotin for adults with muscle-invasive bladder cancer who are ineligible for or refuse cisplatin-based chemotherapy. This approval, based on Phase III VOLGA trial results, offers a new treatment option by demonstrating improved event-free and overall survival for this patient population.